|
| Date |
Time |
Place |
Session / Title |
Role |
|
| April 27 |
7:00 AM - 7:12 AM |
Room 105, Level 1 |
Current and Ongoing Issues in ACS
Pretreatment with P2Y12 Inhibitors in NSTE-ACS: Selective vs. Routine? |
Lecturer |
| April 27 |
7:00 AM - 8:10 AM |
Room 105, Level 1 |
Current and Ongoing Issues in ACS |
Moderator |
| April 27 |
8:15 AM - 9:15 AM |
Main Arena, Level 3 |
Live Case Session |
Discussant |
| April 27 |
11:00 AM - 11:10 AM |
Coronary & Valve Theater, Level 1 |
TCT @ TCTAP 2016: Late-Breaking Trials, Controversies and Hot Topics
The DAPT Duration Debate - Practical Synthesis and Clinical Recommendations |
Lecturer |
| April 27 |
12:00 PM - 12:30 PM |
Interview Lounge, Level 2 |
ACS and Pharmacotherapy |
Interviewee |
| April 27 |
2:42 PM - 2:54 PM |
Room 105, Level 1 |
ACC-i2 @ TCTAP 2016
The DAPT Debate - 2016 |
Lecturer |
| April 27 |
3:15 PM - 4:15 PM |
Room 205, Level 2 |
Meet the Expert |
|
| April 27 |
3:35 PM - 3:55 PM |
Room 205, Level 2 |
Meet the Expert
Balancing Ischemic and Bleeding Risk with DAPT & Experience with Ticagrelor in US |
Lecturer |
| April 27 |
4:30 PM - 6:00 PM |
The Latest Update "Presentation Theater", Level 1 |
ACS and Pharmacotherapy - Making the Right Decision |
Panelist |
| April 27 |
5:22 PM - 5:30 PM |
The Latest Update "Presentation Theater", Level 1 |
ACS and Pharmacotherapy - Making the Right Decision
Revisiting Anticoagulants: Why Dual Pathway Inhibition Is Not Back? |
Lecturer |
| April 27 |
6:25 PM - 6:40 PM |
The Latest Update "Presentation Theater", Level 1 |
Address the CAD Challenge; The Future of Antiplatelet Therapy
Optimal Initiation and Duration of DAPT in ACS Patient; Reviewing the Evidence of Ticagrelor |
Lecturer |
| April 28 |
7:00 AM - 8:10 AM |
Room 105, Level 1 |
Vulnerable Plaque |
Panelist |
| April 28 |
7:00 AM - 7:12 AM |
Room 105, Level 1 |
Vulnerable Plaque
Vulnerable Plaque Is a Systemic Disease: Insights from BioImage |
Lecturer |
| April 28 |
8:30 AM - 10:30 AM |
The Latest Update "Presentation Theater", Level 1 |
New DES & BVS |
Panelist |
| April 28 |
9:18 AM - 9:26 AM |
The Latest Update "Presentation Theater", Level 1 |
New DES & BVS
Optimal DAPT Duration for Current and Future DES and BVS |
Lecturer |
| April 28 |
10:30 AM - 11:26 AM |
The Latest Update "Presentation Theater", Level 1 |
Late Breaking Clinical Trials & 2016 New Data from AMC |
Panelist |
| April 28 |
10:38 AM - 10:44 AM |
The Latest Update "Presentation Theater", Level 1 |
Late Breaking Clinical Trials & 2016 New Data from AMC
Discussion
Late Breaking Clinical Trials: [TCTAP A-001] The Temporal Trends of Incidence, Treatment and In-Hospital Mortality of Acute Myocardial Infarction over 15 Years in Taiwanese Population |
Discussant |
| April 28 |
12:50 PM - 1:05 PM |
Endovascular Theater, Level 1 |
Evolution of Antiplatelet Treatment in ACS and Stable CAD
Upcoming Trend in ACS Patient Management |
Lecturer |
| April 28 |
1:20 PM - 1:35 PM |
The Latest Update "Presentation Theater", Level 1 |
New Technologies That Maximize Procedural Outcome and Long-Term Benefits
EPC Capture Stent : A Promising Solution Amongst the DAPT Controversy? |
Lecturer |
| April 28 |
2:00 PM - 3:00 PM |
Room 203, Level 2 |
Meet the Expert |
|
| April 28 |
2:05 PM - 2:25 PM |
Room 203, Level 2 |
Meet the Expert
Balancing Ischemic and Bleeding Risk with DAPT & Experience with Ticagrelor in US (Updated Guideline) |
Lecturer |
|
